BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

AACR data propel Syndax shares Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) rose $7.99 (69%) to $19.50 on Tuesday after presenting initial data from the Phase I/II AUGMENT-101 trial of SNDX-5613 that showed responses in two out of...
BioCentury | Apr 21, 2020
Product Development

April 20 Quick Takes: Top-line data for BMS, Idorsia and Ascendis; plus Otsuka-Esperion, Regeneron and more

BMS combo meets in Phase III for malignant pleural mesothelioma  Bristol Myers Squibb Co. (NYSE:BMY) said top-line results from the Phase III CheckMate -743 trial showed a combination of anti-PD-1 mAb Opdivo nivolumab and anti-CTLA4...
BC Extra | Jan 22, 2020
Clinical News

BeiGene gearing up for PD-1 competition with Merck, Innovent in 1L squamous NSCLC in China

BeiGene announced Tuesday that tislelizumab met the primary endpoint in a Chinese Phase III trial for first-line squamous non-small cell lung cancer. The readout keeps BeiGene’s PD-1 mAb on track as it vies with Innovent’s...
BC Extra | Jan 13, 2020
Company News

Jan. 13 Company Quick Takes: AZ ends fish oil trial; plus Lynparza, Lilly-NextCure, Innovent, Amgen-Qiagen-Guardant, Axsome-Pfizer

AstraZeneca ends CV outcomes trial of Epanova  AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued the Phase III STRENGTH trial after an IDMC determined it is unlikely to show that Epanova improved cardiovascular outcomes in patients with mixed...
BC Extra | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

Five multinational originator companies were among the winning bidders in China’s national expansion of its centralized procurement program for generic and off-patent drugs in a process that saw steep price cuts and more robust participation...
BC Extra | May 24, 2019
Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
BC Week In Review | Apr 19, 2019
Company News

FDA expands Keytruda's NSCLC indications

Merck said FDA approved Keytruda pembrolizumab as monotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC) and advanced NSCLC in patients who are not candidates for surgical resection or definitive chemoradiation. Patients' tumors...
BC Week In Review | Mar 22, 2019
Company News

EC approves Keytruda for first-line NSCLC regardless of PD-L1 expression

Merck & Co. said the European Commission approved Keytruda pembrolizumab plus carboplatin and either paclitaxel or Abraxane nab-paclitaxel as first-line treatment of metastatic, squamous non-small cell lung cancer regardless of PD-L1 expression. Merck & Co....
BC Week In Review | Nov 30, 2018
Company News

NICE recommends Keytruda combo in first-line NSCLC

U.K.’s NICE recommended in draft guidance anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for use in combination with chemotherapy through the Cancer Drug Fund for untreated, metastatic non-squamous non-small cell lung cancer....
BC Extra | Nov 22, 2018
Company News

NICE recommends Keytruda combo in first-line NSCLC

U.K.’s NICE recommended in draft guidance anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for use in combination with chemotherapy through the Cancer Drug Fund for untreated, metastatic non-squamous non-small cell lung cancer....
Items per page:
1 - 10 of 375